On September 8, 2005, Kallander, Lara S.; Lu, Qing; Chen, Wenfang; Tomaszek, Thaddeus; Yang, Guang; Tew, David; Meek, Thomas D.; Hofmann, Glenn A.; Schulz-Pritchard, Christina K.; Smith, Ward W.; Janson, Cheryl A.; Ryan, M. Dominic; Zhang, Gui-Feng; Johanson, Kyung O.; Kirkpatrick, Robert B.; Ho, Thau F.; Fisher, Paul W.; Mattern, Michael R.; Johnson, Randall K.; Hansbury, Michael J.; Winkler, James D.; Ward, Keith W.; Veber, Daniel F.; Thompson, Scott K. published an article.Category: triazoles The title of the article was 4-Aryl-1,2,3-triazole: A Novel Template for a Reversible Methionine Aminopeptidase 2 Inhibitor, Optimized To Inhibit Angiogenesis in Vivo. And the article contained the following:
Inhibitors of human methionine aminopeptidase type 2 (hMetAP2) are of interest as potential treatments for cancer. A new class of small mol. reversible inhibitors of hMetAP2 was discovered and optimized, the 4-aryl-1,2,3-triazoles. Compound (I), a potent inhibitor of cobalt-activated hMetAP2, also inhibits human and mouse endothelial cell growth. Using a mouse matrigel model, this reversible hMetAP2 inhibitor was also shown to inhibit angiogenesis in vivo. The experimental process involved the reaction of 4-(p-Tolyl)-1H-1,2,3-triazole(cas: 5301-96-2).Category: triazoles
The Article related to aryltriazole derivative preparation methionine aminopeptidase inhibitor angiogenesis, Pharmacology: Structure-Activity and other aspects.Category: triazoles
Referemce:
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics